Data from subjects receiving intrathecal laronidase for cervical spinal stenosis due to mucopolysaccharidosis type I
Five subjects with mucopolysaccharidosis type I and symptomatic cervical spinal stenosis received intrathecal laronidase in a 4-month pilot study and/or a 12-month extension study [1]. Clinical descriptions of study subjects, nonserious adverse events, individual data tables, and scoring system meth...
Main Authors: | P.I. Dickson, I. Kaitila, P. Harmatz, A. Mlikotic, A.H. Chen, A. Victoroff, M.B. Passage, J. Madden, S.Q. Le, D.E. Naylor |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2015-12-01
|
Series: | Data in Brief |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352340915001602 |
Similar Items
-
The impact of laronidase treatment in otolaryngological manifestations of patients with mucopolysaccharidosis
by: Ana Paula Fiuza Funicello Dualibi, et al. -
Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I
by: Roberto Giugliani, et al.
Published: (2017-03-01) -
Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: A systematic review and meta-analysis.
by: Alícia Dorneles Dornelles, et al.
Published: (2017-01-01) -
Transcranial pulsed ultrasound facilitates brain uptake of laronidase in enzyme replacement therapy for Mucopolysaccharidosis type I disease
by: Yu-Hone Hsu, et al.
Published: (2017-06-01) -
Real-world data assessment of safety of home-based and hospital/outpatient-based laronidase enzyme replacement therapy for mucopolysaccharidosis I
by: Amanda Wilson, et al.
Published: (2021-06-01)